SG10202001065SA - Compositions and methods for treating neurodegenerative diseases - Google Patents

Compositions and methods for treating neurodegenerative diseases

Info

Publication number
SG10202001065SA
SG10202001065SA SG10202001065SA SG10202001065SA SG10202001065SA SG 10202001065S A SG10202001065S A SG 10202001065SA SG 10202001065S A SG10202001065S A SG 10202001065SA SG 10202001065S A SG10202001065S A SG 10202001065SA SG 10202001065S A SG10202001065S A SG 10202001065SA
Authority
SG
Singapore
Prior art keywords
compositions
methods
neurodegenerative diseases
treating neurodegenerative
treating
Prior art date
Application number
SG10202001065SA
Inventor
Michael J Brownstein
Original Assignee
Azevan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azevan Pharmaceuticals Inc filed Critical Azevan Pharmaceuticals Inc
Publication of SG10202001065SA publication Critical patent/SG10202001065SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
SG10202001065SA 2014-03-28 2015-03-27 Compositions and methods for treating neurodegenerative diseases SG10202001065SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461971862P 2014-03-28 2014-03-28

Publications (1)

Publication Number Publication Date
SG10202001065SA true SG10202001065SA (en) 2020-04-29

Family

ID=54196457

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202001065SA SG10202001065SA (en) 2014-03-28 2015-03-27 Compositions and methods for treating neurodegenerative diseases
SG11201608064WA SG11201608064WA (en) 2014-03-28 2015-03-27 Compositions and methods for treating neurodegenerative diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201608064WA SG11201608064WA (en) 2014-03-28 2015-03-27 Compositions and methods for treating neurodegenerative diseases

Country Status (22)

Country Link
US (4) US9802925B2 (en)
EP (1) EP3122743B1 (en)
JP (2) JP7255967B2 (en)
KR (2) KR20160130853A (en)
CN (3) CN116327950A (en)
AU (2) AU2015237253B2 (en)
BR (1) BR112016022575A2 (en)
CA (1) CA2944211C (en)
DK (1) DK3122743T3 (en)
ES (1) ES2939959T3 (en)
FI (1) FI3122743T3 (en)
IL (1) IL248074B (en)
MX (2) MX2016012645A (en)
MY (1) MY184878A (en)
NZ (1) NZ724718A (en)
PL (1) PL3122743T3 (en)
RU (1) RU2742773C2 (en)
SG (2) SG10202001065SA (en)
SI (1) SI3122743T1 (en)
TW (1) TWI736519B (en)
WO (1) WO2015148962A1 (en)
ZA (1) ZA201606673B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2587919T3 (en) 2010-07-01 2018-05-30 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
MY184878A (en) 2014-03-28 2021-04-29 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
TWI622380B (en) * 2017-01-17 2018-05-01 正崴精密工業股份有限公司 Physiological Signal Measuring Device and Blood Oxygen Calculation Method
CN111295373A (en) * 2017-09-15 2020-06-16 阿泽凡药物公司 Compositions and methods for treating brain injury
US20240124394A1 (en) * 2020-12-23 2024-04-18 Celgene Corporation Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases
WO2023164710A1 (en) * 2022-02-28 2023-08-31 The Trustees Of Columbia University In The City Of New York Avpr1a blockade to reduce social isolation-induced anxiety in females

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (en) 1975-03-20 1976-09-22 Philips Nv CONNECTIONS WITH ANTIDEPRESSIVE ACTION.
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4341698A (en) 1979-06-21 1982-07-27 Richardson-Merrell Inc. Enkaphalin derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS56125361A (en) 1980-03-07 1981-10-01 Sagami Chem Res Center Azetidinone compound
JPS6033439B2 (en) 1980-03-07 1985-08-02 財団法人相模中央化学研究所 Method for producing dipeptide
FR2508035A1 (en) 1981-06-23 1982-12-24 Fabre Sa Pierre ARYL-1-AMINOMETHYL-2 CYCLOPROPANES CARBOXAMIDE (Z) DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4751299A (en) 1983-11-18 1988-06-14 Takeda Chemical Industries, Ltd. Optically active β-lactams and method of their production
US4665171A (en) 1985-07-17 1987-05-12 Harvard University Process and intermediates for β-lactam antibiotics
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4734498A (en) 1986-07-10 1988-03-29 Eli Lilly And Company 3β-succinimidoazetidinones as chiral intermediates
US4772694A (en) 1986-07-24 1988-09-20 Eli Lilly And Company Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
GB9204001D0 (en) 1992-02-25 1992-04-08 Jacobs Suchard Ag Process for producing reduced fat nuts
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5612336A (en) 1992-07-13 1997-03-18 Merck, Sharp & Dohme Ltd. Heterocyclic amide derivatives as tachykinin antagonists
ES2153841T3 (en) 1992-08-13 2001-03-16 Warner Lambert Co TACIKININE ANTAGONISTS.
FR2696178B1 (en) 1992-09-30 1994-12-30 Sanofi Elf Quaternary basic amides, process for their preparation and pharmaceutical compositions containing them.
ATE158580T1 (en) 1993-05-06 1997-10-15 Merrell Pharma Inc SUBSTITUTED PYRROLIDINE-3-ALKYL-PIPERIDINE USABLE AS TACHYKININ ANTAGONISTS
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5759865A (en) 1995-05-03 1998-06-02 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
ATE305781T1 (en) 1996-02-23 2005-10-15 Lilly Co Eli NON-PEPTIDIC VASOPRESSIN VIA ANTAGONISTS
EP1000062B1 (en) 1997-07-30 2004-09-22 Wyeth Tricyclic vasopressin agonists
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
PL193086B1 (en) 1997-10-27 2007-01-31 Reddys Lab Ltd Dr Novel tricyclic compounds and their medical applications, method of obtaining them and pharmacological compositions containing such compounds
BR0013366A (en) 1999-08-16 2002-07-23 Revaax Pharmaceuticals Llc Methods to treat a behavioral disorder, a human patient, prostate disease, anxiety and cognitive disorders in a human patient afflicted with a condition or willing to develop a condition distinguished at least in part by the concentration of abnormal extracellular glutamate in the brain or in other nervous tissue, behavioral disorder in human, canine, feline and equine species and a patient afflicted with or willing to develop a disease comprising abnormally high glutamate concentrations in neuronal tissue or elevated naaladase levels in prostate tissue and with multiple sclerosis and to enhance cognitive function, pharmaceutical formulation and uses of an inhibitor of peptidase activity of an acidic dipeptidase bound in n-acetylated alpha and a beta-lactam compound
GB0019006D0 (en) 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
JP4494015B2 (en) 2001-10-12 2010-06-30 アゼヴァン ファーマスーティカルズ，インコーポレイテッド β-lactamyl vasopressin V1a antagonist
US7179907B2 (en) 2001-12-18 2007-02-20 Bruce Eaton Antibiotic compounds
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
EP2287166A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
TW200526651A (en) 2003-10-03 2005-08-16 Serenix Pharmaceuticals Llc 3-substituted β-lactamyl vasopressin V1a antagonists
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
EP1669776A1 (en) 2004-12-11 2006-06-14 Leica Geosystems AG Handheld distance measuring apparatus and a method therefore
FR2881744B1 (en) 2005-02-09 2007-04-27 Sanofi Aventis Sa N - [(4,5-DIPHENYL-2-THIENYL) METHYL] AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
WO2006102283A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
CA2608718A1 (en) 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4-triazole derivatives as vasopressin antagonists
CA2615813C (en) * 2005-07-19 2015-12-15 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
WO2007109615A2 (en) 2006-03-21 2007-09-27 Azevan Pharmaceuticals, Inc. β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
US20100016274A1 (en) 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
EP2076517A1 (en) 2006-09-22 2009-07-08 Janssen Pharmaceutica N.V. Spiro benzazepines as vasopressin antagonists
CN101679405A (en) 2007-03-23 2010-03-24 阵列生物制药公司 2-aminopyridine analogs as glucokinase activators
FR2927625B1 (en) 2008-02-19 2010-03-12 Sanofi Aventis NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2930249B1 (en) * 2008-04-21 2010-05-14 Sanofi Aventis NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
PL2587919T3 (en) 2010-07-01 2018-05-30 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
EP2956441A4 (en) 2013-02-18 2016-11-02 Scripps Research Inst Modulators of vasopressin receptors with therapeutic potential
MY184878A (en) 2014-03-28 2021-04-29 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
CN111295373A (en) 2017-09-15 2020-06-16 阿泽凡药物公司 Compositions and methods for treating brain injury

Also Published As

Publication number Publication date
MX2021005502A (en) 2023-01-16
MY184878A (en) 2021-04-29
NZ724718A (en) 2023-04-28
US11319306B2 (en) 2022-05-03
US20200102294A1 (en) 2020-04-02
SI3122743T1 (en) 2023-07-31
AU2015237253B2 (en) 2019-11-14
IL248074B (en) 2020-07-30
AU2019253831A1 (en) 2019-11-14
AU2015237253A1 (en) 2016-10-20
US20170174670A1 (en) 2017-06-22
TW202216702A (en) 2022-05-01
KR20220151037A (en) 2022-11-11
IL248074A0 (en) 2016-11-30
US20180201608A1 (en) 2018-07-19
RU2016138349A3 (en) 2018-10-26
ZA201606673B (en) 2019-06-26
DK3122743T3 (en) 2023-02-20
US20230123729A1 (en) 2023-04-20
US9802925B2 (en) 2017-10-31
JP2017510645A (en) 2017-04-13
JP2022116001A (en) 2022-08-09
CA2944211A1 (en) 2015-10-01
CN116139282A (en) 2023-05-23
CN106459021A (en) 2017-02-22
AU2019253831B2 (en) 2021-10-28
RU2016138349A (en) 2018-05-04
TW201620902A (en) 2016-06-16
US10364236B2 (en) 2019-07-30
EP3122743A4 (en) 2017-11-29
EP3122743A1 (en) 2017-02-01
ES2939959T3 (en) 2023-04-28
MX2016012645A (en) 2017-01-11
PL3122743T3 (en) 2023-05-02
TWI736519B (en) 2021-08-21
RU2742773C2 (en) 2021-02-10
FI3122743T3 (en) 2023-03-02
JP7255967B2 (en) 2023-04-11
WO2015148962A1 (en) 2015-10-01
SG11201608064WA (en) 2016-10-28
CN116327950A (en) 2023-06-27
CN106459021B (en) 2023-04-07
CA2944211C (en) 2022-10-04
KR20160130853A (en) 2016-11-14
EP3122743B1 (en) 2022-11-09
BR112016022575A2 (en) 2017-08-15

Similar Documents

Publication Publication Date Title
HK1225651A1 (en) Isoindoline compositions and methods for treating neurodegenerative disease
HK1232141A1 (en) Methods and compositions for treating huntingtons disease
IL255421A0 (en) Compositions and methods of treating a neurodegenerative disease
SG11201705093UA (en) Composition for treating il-6-related diseases
IL246791A0 (en) Compositions and methods for treating ocular diseases
EP2953950A4 (en) Compositions and methods for treating neurodegenerative diseases
SI3200815T1 (en) Methods and compositions for treating cancer
IL247699A0 (en) Compositions and methods for treating kidney disorders
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
HUE054204T2 (en) Compositions and methods for treating and preventing inflammation
IL249098A0 (en) Methods and compositions for treating allergy and inflammatory diseases
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
HK1245127A1 (en) Methods and compositions for treating brain diseases
ZA201606199B (en) Compositions and methods for treating diabetes and liver diseases
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
ZA201605109B (en) Compositions and methods for treating neutropenia
HK1246206A1 (en) Compositions and methods for treating glaucoma
EP3107534A4 (en) Compositions and methods for the treatment of neurodegenerative diseases
EP3364965A4 (en) Methods and compositions for treating neurodegenerative diseases
HK1244782A1 (en) Compositions and methods for treating diseases and conditions
GB201420348D0 (en) Compounds for treating neurodegenerative diseases
GB201521083D0 (en) Compositions for treatment and methods thereof
GB201419559D0 (en) Therapeutic compositions and methods
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes